Published on 02/12/2025

Regulatory Language for ATMP PPQ/CPV

Advanced Therapy Medicinal Products (ATMPs) are increasingly relevant in modern therapeutic strategies, necessitating rigorous validation protocols tailored to ensure safety and efficacy. This guide serves as a comprehensive resource for professionals in pharmaceuticals and biotechnology, specifically focusing on the Process Performance Qualification (PPQ) and Continued Process Verification (CPV) aspects for ATMPs.

Understanding ATMPs and the Need for Validation

ATMPs encompass a range of biological products, including gene therapies, somatic cell therapies, and tissue-engineered products. Their unique complexity and the specific manufacturing conditions required propel the demand for tailored validation processes. Regulatory bodies such as the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) recognize the necessity for tailored approaches to PPQ and CPV for ATMPs.

The overarching goals of validation include:

• Ensuring the identity, potency, and overall quality of the product.
• Verifying that manufacturing processes are capable of consistently producing products meeting quality specifications.
• Establishing controls over manufacturing steps, particularly in closed and single-use systems.

Regulatory Framework for ATMP Validation

The regulatory framework for ATMPs necessitates adhering to guidelines established by major authorities, such as the FDA’s guidance on process validation, which integrates both PPQ and CPV as pivotal components. Guidelines like ICH Q5A(R2) specify critical parameters for validating viral clearance, which is fundamental in the manufacturing of ATMPs, especially to mitigate risks associated with viral contamination.

Also included in this framework are relevant directives addressing the aseptic processing of ATMPs and contamination control measures. Key to success is integrating proper aseptic controls aligned with Annex 1 of the ICH Quality Guidelines to ensure robust manufacturing practices.

Step-by-Step Guide to PPQ for ATMPs

The PPQ process entails several organized steps to establish and verify the manufacturing process of ATMPs:

Step 1: Design and Development of the Manufacturing Process

The first phase involves harmonizing both laboratory and clinical production processes. Critical Quality Attributes (CQAs)—such as potency and identity—must be defined early, and robust design controls must be established. This phase focuses on:

• Mapping out the entire manufacturing process to identify critical inputs and outputs.
• Conducting risk assessments to determine the potential failure modes.
• Assembling a multidisciplinary team of scientists and engineers to oversee the design.

Step 2: Determining Process Parameters

Identify parameters that affect CQAs, focusing on those having a direct correlation to product quality. This includes temperature, pressure conditions, and time during critical steps. The inclusion of real-time data acquisition systems can greatly enhance understanding and monitoring.

Step 3: Conducting Spiking and Viral Clearance Studies

Robust viral clearance validation is critical for ATMPs, necessitating spiking studies to assess the efficacy of the viral clearance steps implemented in the manufacturing process. During this phase:

• Simulate worst-case scenarios by introducing known quantities of model viruses during the purification process.
• Evaluate the removal or inactivation of viruses under varying conditions to validate the effectiveness of the steps.
• Ensure that experimental conditions mirror production scenarios as realistically as possible.

Step 4: Process Performance Qualification Studies

PPQ studies are executed at three stages of the process—beginning, middle, and end—to verify that each critical step operates as intended:

• Perform multiple runs to evaluate consistency; typically, a minimum of three independent runs.
• Review documentation comprehensively, ensuring that results and process performance meet predetermined criteria.
• Document all findings rigorously to ensure regulatory compliance and transparency.

Continuing with CPV in ATMPs

Once PPQ is established and successfully executed, CPV becomes integral to maintaining process control over time. This ongoing assurance mechanism provides confidence that the process remains within the specified parameters and that any deviations are thoroughly investigated.

Establishing a CPV Plan

Creating a CPV plan necessitates a multifaceted approach to monitoring the manufacturing process post-qualification.

• Identify key performance indicators (KPIs) related to CQAs to monitor continuously.
• Conduct regular audits and review of process variations to ensure any potential drift from established parameters is addressed.
• Implement trend analysis and control charts to facilitate proactive identification of issues.

Documentation and Compliance

Documentation is paramount in both PPQ and CPV stages. Comprehensive records not only ensure compliance with regulatory requirements but also provide insights into operational performance. Essential documentation should include:

• Quality Assurance (QA) documentation affirming compliance with applicable regulatory standards.
• Batch records, including details of batch variances and corrective actions taken.
• Regular reports summarizing performance trends, deviations, and their resolutions.

The Role of Closed and Single-Use Systems in ATMP Validation

Modern ATMP manufacturing increasingly relies on closed systems and single-use systems for aseptic processing. These systems play a pivotal role in maintaining sterility and reducing contamination risks associated with traditional multi-use systems.

Benefits of Single-Use and Closed Systems

• *Enhanced Safety*: Reduced risk of cross-contamination and ease of clean-room maintenance.
• *Cost-Efficiency*: Lower long-term costs associated with cleaning and validating cleaning processes.
• *Flexibility*: Adaptable for various processes, allowing manufacturers to respond to changes quickly.

Validation of Single-Use Systems

Each single-use system used in the process must be validated as part of the overall PPQ. Ensure that:

• The manufacturer provides Certificates of Validation.
• Compatibility with the process is confirmed through robust testing for leachables and extractables.
• All critical operations and removal mechanisms are thoroughly assessed.

Conclusion

In conclusion, the tailored validation of PPQ and CPV processes for ATMPs is integral to ensuring the safe and efficacious delivery of advanced therapies. The intricate relationship between viral clearance, understanding CQAs, and employing modern systems such as closed and single-use pathways significantly enhances the reliability of the manufacturing process. By adhering to the regulatory frameworks established by regulatory bodies such as the FDA, EMA, and MHRA, pharmaceutical professionals can navigate the complexities of ATMP validation successfully and maintain compliance.

By systematically following this guide, professionals can build a robust validation methodology that addresses the unique challenges posed by ATMPs in compliance with international regulatory standards.